Spinraza, also known as nusinersen, is a medicine used to treat spinal muscular atrophy (SMA) in children and adults. SMA is a genetic disease that is passed down through families. It leads to ...

Spinraza (nusinersen) is a prescription drug used to treat spinal muscular atrophy. Spinraza can cause side effects that range from mild to serious. Examples include headache and fever.

Biogen BIIB will report fourth-quarter and full-year 2024 results on Feb. 12, before market open. In the last reported ...

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.

Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken 14 days apart can deliver significant clinical benefits in patients with ...

What is SPINRAZA and its current approval status? SPINRAZA is an approved treatment for spinal muscular atrophy in over 71 countries, currently delivered at a dose of 12 mg. Disclaimer ...

Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...

Three patients with spinal muscular atrophy had improved muscle strength and could walk farther after a month of daily spinal stimulation.

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

From February 12, all newborn babies will be offered screening for spinal muscular atrophy (SMA), a rare progressive neuromuscular disease. SMA will be one of more than 20 other rare disorders ...

A new spinal cord implant may help people with spinal muscular atrophy (SMA) regain some muscle function, giving them ...